Article
Biotechnology & Applied Microbiology
Qiaomai Xu, Shumeng Zhang, Jiazheng Quan, Zhengjie Wu, Silan Gu, Yunbo Chen, Beiwen Zheng, Longxian Lv, Lanjuan Li
Summary: Vancomycin is the preferred treatment for CDI but has a high recurrence rate. FMT has emerged as a successful treatment for recurrent CDI. Our study suggests that FMT can better restore gut microbiota and metabolites, promoting the recovery of colonization resistance in mice compared to vancomycin.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Shaodong Wei, Martin Iain Bahl, Simon Mark Dahl Baunwall, Jens Frederik Dahlerup, Christian Lodberg Hvas, Tine Rask Licht
Summary: This study aimed to explore the relationship between early changes in the intestinal microbiota and clinical outcomes following fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (CDI). The results showed that patients with sustained resolution after FMT had different microbial diversity, abundance, and gut microbiota dysbiosis compared to non-responders. Additionally, a constructed index based on clinically feasible methods successfully predicted treatment failure. It was also found that FMT had a more pronounced impact on the gut microbiota compared to antibiotic monotherapy. Therefore, early identification of microbial community structures after FMT is clinically valuable for predicting treatment response.
Article
Medicine, General & Internal
Pei-Chang Lee, Tien-En Chang, Yen-Po Wang, Kuei-Chuan Lee, Yi-Tsung Lin, Jen-Jie Chiou, Chi-Wei Huang, Ueng-Cheng Yang, Fen-Yau Li, Hui-Chun Huang, Chun-Ying Wu, Yi-Hsiang Huang, Ming-Chih Hou
Summary: This study aimed to investigate the efficacy of FMT for treating rCDI and its association with microbial changes. The research found that successful FMT was related to treatment outcomes and led to dynamic changes in fecal microbial composition.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Immunology
Elizabeth S. Aby, Byron P. Vaughn, Eva A. Enns, Radha Rajasingham
Summary: This study assessed the cost-effectiveness of fecal microbiota transplantation (FMT) for first recurrent Clostridioides difficile infection (CDI). The findings indicate that FMT is a cost-effective treatment strategy for first recurrent CDI.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Gastroenterology & Hepatology
Maribeth R. Nicholson, Suchitra K. Hourigan, Maire Conrad, Alka Goyal, Kyle Jensen, Judith Kelsen, Melissa Kennedy, Madison Weatherly, Stacy A. Kahn
Summary: The impact of the 2019 US FDA safety alert and the COVID-19 pandemic on the use of FMT in children has led to changes in practices for many pediatric gastroenterologists, with a majority of programs being halted as a result.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Tanveer Singh, Prabhjot Bedi, Karandeep Bumrah, Darshan Gandhi, Tanureet Arora, Nikita Verma, Mary Schleicher, Manoj P. Rai, Rajat Garg, Beni Verma, Madhusudhan R. Sanaka
Summary: Fecal microbiota transplantation (FMT) is effective in the treatment of recurrent Clostridium difficile infection (CDI), but not significant in primary CDI.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2022)
Review
Gastroenterology & Hepatology
Avnish Sandhu, Teena Chopra
Summary: Clostridioides difficile infection (CDI) is a major cause of hospital-acquired infections, with recurrent CDI (rCDI) posing a challenge in treatment. Fecal microbiota transplantation (FMT) is suggested for second episodes of rCDI, showing promise compared to traditional treatments like vancomycin or fidaxomicin. However, concerns over infections, adverse events, and new diagnoses remain, requiring further study for long-term safety and efficacy of FMT in clinical practice.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2021)
Review
Gastroenterology & Hepatology
Aravind Gokul Tamilarasan, Thanuja Krishnananthan
Summary: In recent years, significant progress has been made in the study of the intestinal microbiota, with research moving beyond the laboratory and into clinical applications like fecal microbiota transplantation. Studies have shown interesting associations between imbalances in the intestinal microbiota and disease development, highlighting the potential therapeutic benefits of fecal microbiota transplantation in reversing this process.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jessica El Halabi, Nathan Palmer, Kathe Fox, Isaac Kohane, Maha R. Farhat
Summary: This study found that the cases of CDI in the US have been increasing over the past decade, with a changing treatment landscape due to the adoption of FMT. FMT is strongly associated with a decrease in CDI recurrence compared to anti-CDI antibiotics, with potential gastrointestinal complications and sepsis in the short term post FMT.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Multidisciplinary Sciences
Olle Bjorkqvist, Ignacio Rangel, Lena Serrander, Cecilia Magnusson, Jonas Halfvarson, Torbjorn Noren, Malin Bergman-Jungestrom
Summary: The study found that FMT can increase the relative abundance of Faecalibacterium prausnitzii in patients with recurrent CDI, and this microbial shift persists for several months later. Further research is needed to determine whether Faecalibacterium prausnitzii actively contributes to the resolution of CDI.
Article
Microbiology
Craig Haifer, Sudarshan Paramsothy, Thomas J. Borody, Annabel Clancy, Rupert W. Leong, Nadeem O. Kaakoush
Summary: Oral lyophilized fecal microbiota transplantation (FMT) is effective in treating Clostridioides difficile infection (CDI), improving microbial diversity and resulting in durable engraftment up to 6 months post-treatment, with better efficacy observed in primary CDI compared to recurrent cases. Changes in bacterial and fungal communities are associated with therapy outcomes.
Article
Geriatrics & Gerontology
Massimo Montalto, Antonella Gallo, Maria Chiara Agnitelli, Simona Pellegrino, Alice Lipari, Erika Pero, Marcello Covino, Francesco Landi, Antonio Gasbarrini, Giovanni Cammarota, Gianluca Ianiro
Summary: Fecal microbiota transplantation (FMT) is effective and safe for very old patients with recurrent Clostridioides difficile infection (rCDI). Frailty and high comorbidity do not limit the use of FMT in these patients. Frailty assessment has the potential to better identify patients at higher risk for worse outcomes or repeat treatment with FMT.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2023)
Review
Biochemistry & Molecular Biology
Adrian Boicean, Victoria Birlutiu, Cristian Ichim, Paula Anderco, Sabrina Birsan
Summary: Inflammatory bowel diseases (IBD) are complex diseases characterized by chronic inflammation in the gastrointestinal tract. Fecal microbiota transplantation (FMT) has shown increasing effectiveness and safety in treating recurrent Clostridium difficile infection (CDI) and co-infection of SARS-CoV-2 and CDI. By modifying the gut microbiota, FMT offers an alternative approach to indirectly influence the host's immune system in a safe way, improving clinical symptoms and endoscopic findings in IBD patients. Further validation is needed to establish a clinical protocol for FMT in IBD.
Review
Gastroenterology & Hepatology
Lucas F. Soveral, Gabriela G. Korczaguin, Pedro S. Schmidt, Isabel S. Nunes, Camilo Fernandes, Carlos R. Zarate-Blades
Summary: Fecal microbiota transplantation (FMT) is a successful method for treating recurrent Clostridioides difficile (C. difficile) infection. It works through direct mechanisms against C. difficile and indirect mechanisms involving the production of secondary bile acids and short chain fatty acids. Furthermore, FMT can modulate the inflammatory response triggered by C. difficile by regulating regulatory T cells, resulting in the normalization of the intestinal mucosal immune system.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Adrian Boicean, Victoria Birlutiu, Cristian Ichim, Olga Brusnic, Danusia Maria Onisor, Amedeo Amedei, Ryota Niikura
Summary: Imbalances in the gut microbiota play a crucial role in the development of liver diseases, and fecal microbiota transplantation has shown promise as an effective treatment for chronic liver diseases and cirrhosis.
Letter
Gastroenterology & Hepatology
William Chamberlin, Thomas Borody
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2019)
Article
Gastroenterology & Hepatology
Sudarshan Paramsothy, Shaun Nielsen, Michael A. Kamm, Nandan P. Deshpande, Jeremiah J. Faith, Jose C. Clemente, Ramesh Paramsothy, Alissa J. Walsh, Johan van den Bogaerde, Douglas Samuel, Rupert W. L. Leong, Susan Connor, Watson Ng, Enmoore Lin, Thomas J. Borody, Marc R. Wilkins, Jean-Frederic Colombel, Hazel M. Mitchell, Nadeem O. Kaakoush
Article
Microbiology
Michael C. Wehrhahn, Caitlin Keighley, Jelica Kurtovic, Daniel R. Knight, Stacey Hong, Melanie L. Hutton, Dena Lyras, Qinning Wang, Rupert Leong, Tom Borody, Michael Edye, Thomas V. Riley
Article
Gastroenterology & Hepatology
James B. Adams, Thomas J. Borody, Dae-Wook Kang, Alexander Khoruts, Rosa Krajmalnik-Brown, Michael J. Sadowsky
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2019)
Letter
Gastroenterology & Hepatology
Harveen Singh, Lindsey Ross, Harriet Smith, Thomas J. Borody, Daniel A. Lemberg
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2019)
Article
Gastroenterology & Hepatology
Craig Haifer, Colleen R. Kelly, Sudarshan Paramsothy, David Andresen, Lito E. Papanicolas, Genevieve L. McKew, Thomas J. Borody, Michael Kamm, Samuel P. Costello, Jane M. Andrews, Jakob Begun, Hiu Tat Chan, Susan Connor, Simon Ghaly, Paul D. R. Johnson, Daniel A. Lemberg, Ramesh Paramsothy, Andrew Redmond, Harsha Sheorey, David van der Poorten, Rupert W. Leong
Article
Microbiology
Gaurav Agrawal, Annabel Clancy, Rijata Sharma, Roy Huynh, Sanjay Ramrakha, Thomas Borody
Article
Microbiology
Irina Leonardi, Sudarshan Paramsothy, Itai Doron, Alexa Semon, Nadeem O. Kaakoush, Jose C. Clemente, Jeremiah J. Faith, Thomas J. Borody, Hazel M. Mitchell, Jean-Frederic Colombel, Michael A. Kamm, Iliyan D. Iliev
CELL HOST & MICROBE
(2020)
Article
Gastroenterology & Hepatology
Gaurav Agrawal, Annabel Clancy, Roy Huynh, Thomas Borody
Article
Microbiology
Craig Haifer, Sudarshan Paramsothy, Thomas J. Borody, Annabel Clancy, Rupert W. Leong, Nadeem O. Kaakoush
Summary: Oral lyophilized fecal microbiota transplantation (FMT) is effective in treating Clostridioides difficile infection (CDI), improving microbial diversity and resulting in durable engraftment up to 6 months post-treatment, with better efficacy observed in primary CDI compared to recurrent cases. Changes in bacterial and fungal communities are associated with therapy outcomes.
Article
Gastroenterology & Hepatology
Anoja W. Gunaratne, Harrison Hamblin, Annabel Clancy, Aleja Jane Marie C. Magat, Marie Vic M. Dawson, Jeffrey Tu, Thomas J. Borody
Summary: The study investigated the efficacy and safety of vonoprazan-containing antibiotic combination therapies in eradicating H. pylori infection in an Australian setting. Results showed a high eradication rate of 97% overall, with 100% efficacy in treatment-naive patients and 91% efficacy in those who had previously failed eradication treatment. Further studies are needed to optimize treatment regimens involving multiple antibiotics.
Article
Microbiology
Sabine Hazan, Sonya Dave, Anoja W. Gunaratne, Sibasish Dolai, Robert L. Clancy, Peter A. McCullough, Thomas J. Borody
Summary: This study examined the effectiveness of a combination therapy consisting of ivermectin, doxycycline, zinc, and vitamins D and C in treating COVID-19. The results showed that all patients experienced symptom relief and improved oxygen saturation. The study suggests that this treatment approach is safe and effective for outpatient cases with moderate to severe symptoms.
FUTURE MICROBIOLOGY
(2022)
Letter
Microbiology
Sabine Hazan, Sonya Dave, Thomas J. Borody, Peter A. McCullough
FUTURE MICROBIOLOGY
(2022)
Article
Gastroenterology & Hepatology
Harrison Hamblin, Anoja W. Gunaratne, Annabel Clancy, Denise Pilarinos, Antoinette LeBusque, Marie Vic M. Dawson, Thomas J. Borody
Summary: This study evaluated the safety and efficacy of a six-month fecal microbiota transplantation (FMT) treatment protocol in patients with irritable bowel syndrome (IBS). The results showed that this treatment was able to alleviate IBS symptoms in the short- and long-term, while improving the quality of life for patients.
GASTROENTEROLOGY RESEARCH AND PRACTICE
(2022)
Article
Microbiology
Matthew Z. DeMaere, Michael Y. Z. Liu, Enmoore Lin, Steven P. Djordjevic, Ian G. Charles, Paul Worden, Catherine M. Burke, Leigh G. Monahan, Melissa Gardiner, Thomas J. Borody, Aaron E. Darling
MICROBIOLOGY RESOURCE ANNOUNCEMENTS
(2020)